Drug Type Mesenchymal stem cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis, Primary Progressive | Phase 2 | United Kingdom | 01 Jan 2013 | |
| Multiple Sclerosis, Relapsing-Remitting | Phase 2 | United Kingdom | 01 Jan 2013 | |
| Multiple Sclerosis, Secondary Progressive | Phase 2 | United Kingdom | 01 Jan 2013 |
Phase 1/2 | 21 | Mesenchymal stem cells (A: Mesenchymal Stem Cells First, Then Placebo) | vgoihcsnwe = ntchsumrug ulnffdadxe (jeeepfoozc, rzmwhbpgen - hsxuayseut) View more | - | 14 Jan 2025 | ||
Placebo (B: Placebo First, Then MSCs) | vgoihcsnwe = tschnjzuvl ulnffdadxe (jeeepfoozc, atmboyveui - xdtlsjfole) View more |





